Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert A. Kratzke

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Journal of Thoracic Oncology

English

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

Anesthesia and Analgesia

Anesthesiology

Pain Medicine

2011

English

Related publications

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Journal of Thoracic Oncology

English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research

Cancer Research

Oncology

2017

English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

2020

English

Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Cancer Discovery

Oncology

2016

English

Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC

Molecular Cancer Research

English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports

English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology

English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert A. Kratzke

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

Related publications

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)